Deep Genomics Nominates Industry’s First AI – Discovered Therapeutic Candidate

Deep Genomics, the leading AI therapeutics company, announced today that its proprietary artificial intelligence-based drug discovery platform has identified a novel treatment target and corresponding drug candidate for Wilson disease, a rare, serious, and potentially life-threatening genetic disorder.

Please to read the entire article.

You must be logged in to post a comment Login